{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:21:39Z","timestamp":1784784099085,"version":"3.55.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["R01FD006030"],"award-info":[{"award-number":["R01FD006030"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["HL159376"],"award-info":[{"award-number":["HL159376"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.hoc.2022.06.008","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T22:15:13Z","timestamp":1668550513000},"page":"1285-1312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Evolving Landscape of Drug Therapies for Sickle Cell Disease"],"prefix":"10.1016","volume":"36","author":[{"given":"Parul","family":"Rai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal C.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth I.","family":"Ataga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9757","key":"10.1016\/j.hoc.2022.06.008_bib1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"issue":"9861","key":"10.1016\/j.hoc.2022.06.008_bib2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.hoc.2022.06.008_bib3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3324\/haematol.10937","article-title":"Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London","volume":"92","author":"Telfer","year":"2007","journal-title":"Haematologica"},{"issue":"6 Suppl 4","key":"10.1016\/j.hoc.2022.06.008_bib4","doi-asserted-by":"crossref","first-page":"S398","DOI":"10.1016\/j.amepre.2011.09.013","article-title":"Sickle cell disease in Africa: a neglected cause of early childhood mortality","volume":"41","author":"Grosse","year":"2011","journal-title":"Am J Prev Med"},{"issue":"23","key":"10.1016\/j.hoc.2022.06.008_bib5","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2022.06.008_bib6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/ajh.23683","article-title":"Factors associated with survival in a contemporary adult sickle cell disease cohort","volume":"89","author":"Elmariah","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2022.06.008_bib7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3324\/haematol.2016.153791","article-title":"Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe","volume":"102","author":"Maitra","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.hoc.2022.06.008_bib8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis","volume":"133","author":"DeBaun","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2022.06.008_bib9","unstructured":"Steiner CA, Miller JL: Sickle Cell Disease Patients in U.S. Hospitals, 2006 In:Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb-, Statistical Brief #21."},{"issue":"6","key":"10.1016\/j.hoc.2022.06.008_bib10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ajh.21408","article-title":"The cost of health care for children and adults with sickle cell disease","volume":"84","author":"Kauf","year":"2009","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2022.06.008_bib11","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.hoc.2014.08.014","article-title":"Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions","volume":"28","author":"Fitzhugh","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"10.1016\/j.hoc.2022.06.008_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of lentiglobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.hoc.2022.06.008_bib13","first-page":"e91","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. reply","volume":"384","author":"Frangoul","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2022.06.008_bib14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJM199709113371107","article-title":"Pathogenesis and treatment of sickle cell disease","volume":"337","author":"Bunn","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2022.06.008_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2567.2012.03612.x","article-title":"Turned on by danger: activation of CD1d-restricted invariant natural killer T\u00a0cells","volume":"137","author":"Lawson","year":"2012","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.hoc.2022.06.008_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ajh.21952","article-title":"Reconstructing sickle cell disease: a data-based analysis of the \"hyperhemolysis paradigm\" for pulmonary hypertension from the perspective of evidence-based medicine","volume":"86","author":"Hebbel","year":"2011","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.hoc.2022.06.008_bib17","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nm1202-799","article-title":"Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease","volume":"8","author":"Reiter","year":"2002","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.hoc.2022.06.008_bib18","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.V78.10.2753.2753","article-title":"Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents","volume":"78","author":"Repka","year":"1991","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2022.06.008_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1172\/JCI118074","article-title":"Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines","volume":"96","author":"De Caterina","year":"1995","journal-title":"J\u00a0Clin Invest"},{"issue":"6174","key":"10.1016\/j.hoc.2022.06.008_bib20","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/333664a0","article-title":"Vascular endothelial cells synthesize nitric oxide from L-arginine","volume":"333","author":"Palmer","year":"1988","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.hoc.2022.06.008_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.blre.2006.07.001","article-title":"Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes","volume":"21","author":"Kato","year":"2007","journal-title":"Blood Rev"},{"key":"10.1016\/j.hoc.2022.06.008_bib22","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.hoc.2022.06.008_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ajh.24948","article-title":"A\u00a0randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD)","volume":"93","author":"Tanabe","year":"2018","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.hoc.2022.06.008_bib24","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","article-title":"American society of hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain","volume":"4","author":"Brandow","year":"2020","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.hoc.2022.06.008_bib25","first-page":"1880","article-title":"A\u00a0phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2022.06.008_bib26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2022.06.008_bib27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A\u00a0Phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.hoc.2022.06.008_bib28","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1182\/blood-2017-02-765891","article-title":"Treating sickle cell disease by targeting HbS polymerization","volume":"129","author":"Eaton","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2022.06.008_bib29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.exphem.2008.06.014","article-title":"A\u00a0cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger","volume":"36","author":"Mabaera","year":"2008","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2022.06.008_bib30","first-page":"273","article-title":"Iron chelators hydroxyurea and bathophenanthroline disulfonate inhibit DNA synthesis by different pathways","volume":"34","author":"Alcain","year":"1994","journal-title":"Biochem Mol Biol Int"},{"issue":"2","key":"10.1016\/j.hoc.2022.06.008_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1172\/JCI200316672","article-title":"Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase","volume":"111","author":"Cokic","year":"2003","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.hoc.2022.06.008_bib32","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.freeradbiomed.2006.01.002","article-title":"Rat liver-mediated metabolism of hydroxyurea to nitric oxide","volume":"40","author":"Huang","year":"2006","journal-title":"Free Radic Biol Med"},{"issue":"20","key":"10.1016\/j.hoc.2022.06.008_bib33","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.hoc.2022.06.008_bib34","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2012-03-419879","article-title":"Impact of hydroxyurea on clinical events in the BABY HUG trial","volume":"120","author":"Thornburg","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2022.06.008_bib35","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.hoc.2022.06.008_bib36","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/ajh.26286","article-title":"Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study","volume":"96","author":"de Montalembert","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2022.06.008_bib37","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-hydroxyurea-treatment-pediatric-patients-sickle-cell-anemia"},{"issue":"12","key":"10.1016\/j.hoc.2022.06.008_bib38","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/ajh.24198","article-title":"Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial","volume":"90","author":"Hankins","year":"2015","journal-title":"Am J Hematol"},{"issue":"10019","key":"10.1016\/j.hoc.2022.06.008_bib39","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial","volume":"387","author":"Ware","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.hoc.2022.06.008_bib40","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2007-08-110098","article-title":"Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia","volume":"111","author":"Ataga","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2022.06.008_bib41","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2141.2010.08520.x","volume":"153","author":"Ataga","year":"2011","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2022.06.008_bib42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1021\/acsmedchemlett.6b00491","article-title":"Discovery of GBT440, an orally bioavailable r-state stabilizer of sickle cell hemoglobin","volume":"8","author":"Metcalf","year":"2017","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"10.1016\/j.hoc.2022.06.008_bib43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.14214","article-title":"GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease","volume":"175","author":"Oksenberg","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2022.06.008_bib44","unstructured":"https:www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-voxelotor-sickle-cell-disease"},{"key":"10.1016\/j.hoc.2022.06.008_bib45","unstructured":"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-treat-sickle-cell-disease-patients-aged-4-11-years#:\u223c:text=FDA%20has%20granted%20accelerated%20approval,older%20with%20sickle%20cell%20disease"},{"issue":"5","key":"10.1016\/j.hoc.2022.06.008_bib46","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1111\/bjh.17345","article-title":"Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial","volume":"192","author":"Ataga","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2022.06.008_bib47","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approved-l-glutamine-powder-treatment-sickle-celldisease#:\u223c:text=On%20July%207%2C%202017%2C%20the,patients%205%20years%20and%20older"},{"issue":"3","key":"10.1016\/j.hoc.2022.06.008_bib48","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A\u00a0phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2022.06.008_bib49","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.14809","article-title":"Effect of N-acetylcysteine on pain in daily life in patients with sickle cell disease: a randomised clinical trial","volume":"182","author":"Sins","year":"2018","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.hoc.2022.06.008_bib50","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2014-06-583351","article-title":"Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use","volume":"125","author":"Telen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2022.06.008_bib51","unstructured":"Pfizer Announces Phase 3 Top-Line Results for Rivipansel in Patients with Sickle Cell Disease Experiencing a Vaso-Occlusive Crisis | Pfizer."},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2022.06.008_bib52","article-title":"Early initiation of treatment with rivipansel for acute vaso-occlusive crisis in sickle cell disease (SCD) achieves earlier discontinuation of iv opioids and shorter hospital stay: RESET clinical trial analysis","volume":"136","author":"Carlton","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2022.06.008_bib53","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2019-124653","article-title":"Efficacy and safety of sevuparin, a novelnon-anti-coagulant heparinoid, in patients with acute painful vaso-occlusive crisis; A global, multicenter double-blind, randomized, placebo controlled Phase-2 trial (TVOCO1)","volume":"134","author":"Biedmond Bart","year":"2019","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2022.06.008_bib54","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.286.17.2099","article-title":"Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial","volume":"286","author":"Orringer","year":"2001","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.hoc.2022.06.008_bib55","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jama.2021.11103","article-title":"Poloxamer 188 vs placebo for painful vaso-occlusive episodes in children and adults with sickle cell disease-reply","volume":"326","author":"Casella","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.hoc.2022.06.008_bib56","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/10739680490278402","article-title":"The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy","volume":"11","author":"Hebbel","year":"2004","journal-title":"Microcirculation"},{"issue":"7","key":"10.1016\/j.hoc.2022.06.008_bib57","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ajh.24742","article-title":"Inhaled steroids reduce pain and sVCAM levels in individuals with sickle cell disease: a triple-blind, randomized trial","volume":"92","author":"Glassberg","year":"2017","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.hoc.2022.06.008_bib58","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2141.2010.08480.x","article-title":"A\u00a0pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction","volume":"153","author":"Hoppe","year":"2011","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2022.06.008_bib59","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/bjh.14580","article-title":"Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial","volume":"177","author":"Hoppe","year":"2017","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.hoc.2022.06.008_bib60","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/bloodadvances.2017009613","article-title":"Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease","volume":"1","author":"Field","year":"2017","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.hoc.2022.06.008_bib61","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2018021444","article-title":"Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)","volume":"2","author":"Daak","year":"2018","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.hoc.2022.06.008_bib62","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/blood.2021013674","article-title":"A\u00a0randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia","volume":"139","author":"Rees","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2022.06.008_bib63","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2019001165","article-title":"Phase 2 trial of montelukast for prevention of pain in sickle cell disease","volume":"4","author":"Field","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.hoc.2022.06.008_bib64","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1172\/JCI89741","article-title":"Intravascular hemolysis and the pathophysiology of sickle cell disease","volume":"127","author":"Kato","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.hoc.2022.06.008_bib65","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jama.2011.235","article-title":"Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial","volume":"305","author":"Gladwin","year":"2011","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.hoc.2022.06.008_bib66","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00134-015-4060-2","article-title":"Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: a randomized controlled study","volume":"41","author":"Maitre","year":"2015","journal-title":"Intensive Care Med"},{"issue":"9","key":"10.1016\/j.hoc.2022.06.008_bib67","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3324\/haematol.2013.086637","article-title":"A\u00a0randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes","volume":"98","author":"Morris","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2022.06.008_bib68","doi-asserted-by":"crossref","first-page":"4397150","DOI":"10.1155\/2019\/4397150","article-title":"Double-blind clinical trial of arginine supplementation in the treatment of adult patients with sickle cell anaemia","volume":"2019","author":"Eleuterio","year":"2019","journal-title":"Adv Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2022.06.008_bib69","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ajh.26028","article-title":"Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria","volume":"96","author":"Onalo","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2022.06.008_bib70","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2010-09-306167","article-title":"Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity","volume":"118","author":"Machado","year":"2011","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2022.06.008_bib71","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/blood-2017-05-781849","article-title":"Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study","volume":"130","author":"Heimall","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2022.06.008_bib72","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.2830310404","article-title":"Platelet activation during pain crisis in sickle cell anemia patients","volume":"31","author":"Beurling-Harbury","year":"1989","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2022.06.008_bib73","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2141.2000.02353.x","article-title":"Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia","volume":"111","author":"Inwald","year":"2000","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2022.06.008_bib74","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.thromres.2013.12.008","article-title":"A\u00a0phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation","volume":"133","author":"Jakubowski","year":"2014","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.hoc.2022.06.008_bib75","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/01.ATV.0000220374.00602.a2","article-title":"Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation","volume":"26","author":"Lee","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.hoc.2022.06.008_bib76","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1365-2141.1998.00627.x","article-title":"Platelet activation in patients with sickle cell disease","volume":"100","author":"Wun","year":"1998","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2022.06.008_bib77","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0022-3476(83)80258-3","article-title":"Trial of low doses of aspirin as prophylaxis in sickle cell disease","volume":"102","author":"Greenberg","year":"1983","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.hoc.2022.06.008_bib78","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000207105","article-title":"Therapeutic effect of aspirin in sickle cell anaemia","volume":"66","author":"Osamo","year":"1981","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2022.06.008_bib79","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000206360","article-title":"Treatment of sickle cell diseases with aspirin","volume":"72","author":"Zago","year":"1984","journal-title":"Acta Haematol"},{"key":"10.1016\/j.hoc.2022.06.008_bib80","first-page":"199","article-title":"Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises","volume":"15","author":"Cabannes","year":"1984","journal-title":"Agents Actions Suppl"},{"issue":"7","key":"10.1016\/j.hoc.2022.06.008_bib81","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1512021","article-title":"A\u00a0multinational trial of prasugrel for sickle cell vaso-occlusive events","volume":"374","author":"Heeney","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2022.06.008_bib82","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/ajh.25273","article-title":"A\u00a0dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease: A 2-part phase 2 study","volume":"93","author":"Hsu","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2022.06.008_bib83","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/bjh.15646","article-title":"Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study","volume":"184","author":"Kanter","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2022.06.008_bib84","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1160\/Th06-12-0718","article-title":"Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial","volume":"98","author":"Qari","year":"2007","journal-title":"Thromb Haemost"},{"issue":"S1","key":"10.1016\/j.hoc.2022.06.008_bib85","article-title":"Mitapivat (AG-348) demonstrates safety, tolerability, and improvements in anemia, hemolysis, oxygen affinity, and hemoglobin s polymerization kinetics in adults with sickle cell disease: a phase 1 dose escalation study","volume":"138","author":"Julia","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2022.06.008_bib86","first-page":"8","volume":"138","author":"Theodosia","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2022.06.008_bib87","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-134269","article-title":"FT-4202, an allosteric activator of pyruvate kinase-R, demonstrates proof of mechanism and proof of concept after a single dose and after multiple daily doses in a phase 1 study of patients with sickle cell disease","volume":"136","author":"Brown","year":"2020","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.hoc.2022.06.008_bib88","article-title":"A\u00a0Phase 2\/3, randomized, double-blind, placebo-controlled study of mitapivat in patients with sickle cell disease","volume":"138","author":"Joanna","year":"2021","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.hoc.2022.06.008_bib89","article-title":"Activation of pyruvate kinase-r with etavopivat (FT-4202) is well tolerated, improves anemia, and decreases intravascular hemolysis in patients with sickle cell disease treated for up to 12\u00a0weeks","volume":"138","author":"Brown","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2022.06.008_bib90","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-148-2-200801150-00004","article-title":"Daily assessment of pain in adults with sickle cell disease","volume":"148","author":"Smith","year":"2008","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.hoc.2022.06.008_bib91","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.13548","article-title":"The trials and hopes for drug development in sickle cell disease","volume":"170","author":"Ataga","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2022.06.008_bib92","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.hoc.2022.06.008_bib93","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM199807023390102","article-title":"Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography","volume":"339","author":"Adams","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2022.06.008_bib94","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1056\/NEJMoa050460","article-title":"Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. optimizing primary stroke prevention in sickle cell anemia (STOP 2) trial investigators","volume":"353","author":"Adams","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2022.06.008_bib95","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199107043250103","article-title":"Pain in sickle cell disease. rates and risk factors","volume":"325","author":"Platt","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2022.06.008_bib96","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.V84.2.643.643","article-title":"The acute chest syndrome in sickle cell disease: incidence and risk factors. the cooperative study of sickle cell disease","volume":"84","author":"Castro","year":"1994","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2022.06.008_bib97","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jval.2013.08.2293","article-title":"Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010)","volume":"16","author":"DeMuro","year":"2013","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.hoc.2022.06.008_bib98","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ajh.21905","article-title":"Comprehensive sickle cell centers clinical trial consortium site I: health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium","volume":"86","author":"Dampier","year":"2011","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2022.06.008_bib99","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/pbc.22222","article-title":"Vaso-occlusive painful events in sickle cell disease: impact on child well-being","volume":"54","author":"Brandow","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2022.06.008_bib100","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/pbc.24176","article-title":"Health-related quality of life in sickle cell disease: past, present, and future","volume":"59","author":"Panepinto","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2022.06.008_bib101","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MPH.0b013e3182114c54","article-title":"Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea","volume":"33","author":"Thornburg","year":"2011","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.hoc.2022.06.008_bib102","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1477-7525-4-59","article-title":"Bonds DR: Hydroxyurea and sickle cell anemia: effect on quality of life","volume":"4","author":"Ballas","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.hoc.2022.06.008_bib103","doi-asserted-by":"crossref","first-page":"592","DOI":"10.12688\/f1000research.22433.1","article-title":"Drug therapies for the management of sickle cell disease","volume":"9","author":"Rai","year":"2020","journal-title":"F1000Res"},{"issue":"5","key":"10.1016\/j.hoc.2022.06.008_bib104","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood.V67.5.1442.1442","article-title":"A\u00a0collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis","volume":"67","author":"Benjamin","year":"1986","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2022.06.008_bib105","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJM197403212901204","article-title":"Sodium cyanate as a potential treatment for sickle-cell disease","volume":"290","author":"Gillette","year":"1974","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2022.06.008_bib106","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199403173301101","article-title":"High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease","volume":"330","author":"Griffin","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"9778","key":"10.1016\/j.hoc.2022.06.008_bib107","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.hoc.2022.06.008_bib108","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jama.289.9.1136","article-title":"Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease","volume":"289","author":"Weiner","year":"2003","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.hoc.2022.06.008_bib109","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V92.9.3082","article-title":"Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease","volume":"92","author":"Bernini","year":"1998","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:20:13Z","timestamp":1760185213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858822000661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":109,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0889858822000661"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2022.06.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evolving Landscape of Drug Therapies for Sickle Cell Disease","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2022.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}